FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

Season 10 Episode 19  ·  Mar 11, 2024, 06:00 PM

Headliner
Share
Subscribe

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.

Share
Subscribe
Next
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air